Cryo-Cell International, Inc. (CCEL) AI Stock Analysis

Cryo-Cell International, Inc., headquartered in Oldsmar, Florida, specializes in cellular processing and cryogenic storage. The company focuses on the collection and preservation of umbilical cord blood stem cells primarily for family use. Its cord tissue service stores umbilical cord segments containing mesenchymal stem cells used in regenerative medicine for heart disease, kidney disease, ALS, wound healing, and autoimmune disorders. In addition, Cryo-Cell manufactures and markets the PrepaCyte CB processing system. The company stores approximately 500,000 cord blood and cord tissue stem cells in its global repository, marketing directly to expectant parents and healthcare professionals.

Cryo-Cell posted a 5-year revenue CAGR of 0.3% from FY2020 to FY2025. Annual revenue grew from $28.9M in FY2021 to $30.3M in FY2022, $31.3M in FY2023, and $32.0M in FY2024, before declining 1.3% to $31.6M in FY2025. Gross margin expanded every year, moving from 68.9% in FY2021 to 76.6% in FY2025. Operating margin recovered to 15.3% in FY2025 after falling to -39.3% in FY2023. Net income was -$2.4M with EPS of -$0.27 in FY2025. Trailing twelve month revenue stood at $31.1M with EPS of -$0.24 through the quarter ended August 31, 2026, while quarterly earnings growth was 75.1% year-over-year.

As of August 31, 2026, Cryo-Cell held $4.2M in cash and short-term investments and $577,203 in total debt, yielding net cash of $3.7M. Total assets were $62.3M, shareholders' equity was -$16.4M, and the current ratio was 0.86. The company generated $5.5M in operating cash flow and $5.2M in free cash flow in FY2025. During FY2025, cash deployment included capital expenditures of $230,475, share buybacks of $169,502, and dividends paid of $3.2M, with a 5-year share count change of -3.5%.

Cryo-Cell trades at a market cap of $35.6M and an enterprise value of $38.0M. Its price-to-sales of 1.1x and EV/revenue of 1.2x sit below the median of its US-listed Healthcare peers, which carries a price-to-sales of 4.1x. However, its EV/EBITDA of 50.9x is higher than the peer median of 12.0x, alongside a price-to-book of 9.7x and PEG of 1.34. CCEL shares dropped 1.8% over the past year, trailing the S&P 500 return of 16.8%, and fell 58.1% over five years compared to an 83.0% gain for the index.

Cryo-Cell is covered by 1 analyst who maintains a Buy rating, with 0 Hold and 0 Sell ratings. The mean price target is $8.50, representing a 92.3% premium over the last close of $4.42. For the fiscal year ending November 30, 2027, consensus estimates forecast revenue of $31.5M, EPS of $0.07, and projected EPS growth of 0.0%. Over the trailing four quarters, the company exceeded consensus EPS estimates in 3 quarters.

This page is an AI-written research summary of Cryo-Cell International, Inc. (CCEL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CCEL income statement, CCEL balance sheet, CCEL key metrics, CCEL analyst forecast, CCEL chart. See the CCEL stock overview for the latest quote and news.